Led · Seed · May 2026

Ditto offers an AI-powered app that lets patients record consultations or upload photos of medical letters and then generates summaries that can be revisited later. The platform can translate summaries into simplified language and multiple languages including English, Turkish, and Arabic, and enables secure sharing with family members while stating that no data is stored centrally. The company says its service aims to improve patient understanding, reduce repetitive follow-up questions, and ease administrative pressure on healthcare professionals. Ditto launched last summer and its app has been downloaded nearly 100,000 times. The startup was founded by Tobias Polak, Bart Voorn, and Merlijn van Breugel. Using the new funding, Ditto intends to expand across Europe and build features to help patients prepare for consultations and navigate care journeys together with relatives.

Led · Seed · Sep 2025

FormlyAI has built an artificial-intelligence-driven platform that combines regulatory expertise with machine learning to guide medical device companies through complex certification processes. By automating traditionally manual tasks, the software enables clients to complete certifications up to ten times faster while saving an average of $70,000 in quality-assurance and compliance costs. Users also report reducing time-to-market for their devices by as much as six months, giving innovators a meaningful competitive edge. The platform serves a growing customer base across the European Union and the United States, including collaborations with established consulting firms. With more than 95% of medtech startups lacking in-house regulatory expertise, FormlyAI positions itself as a one-stop solution that eliminates the need for costly consultants and fragmented software tools. The company plans to expand its team and extend operations into Canada and several Asian markets by year-end, using new capital to support these initiatives. FormlyAI aims to become the industry standard for streamlined, affordable certification in the global medtech sector.

Participated · Seed · Apr 2025

CGC Genomics, founded in 2023, develops Qnomx, a regulatory‑grade generative AI platform that interprets NGS cancer genome reports and produces concise, clinically relevant summaries with a human‑in‑the‑loop. The company is developing Qnomx under an ISO 13485‑certified quality management system and aims for regulatory approval compliant with IVDR, MDR and the European AI Act. Internal use has shown substantial efficiency gains—reducing manual interpretation that can take up to two hours to concise summaries delivered in minutes—and the platform is now in pilot validation with Labor Becker and the OnkoMedeor Group. CGC positions Qnomx as a transparent, auditable alternative to unregulated tools currently used in some clinical settings. The startup highlights the market need—rising cancer cases and low NGS uptake—where many oncologists find current NGS reports too complex to act on quickly. Financially, CGC Genomics has secured external support via a pre‑Seed raise to advance product development and regulatory milestones.

Participated · Series A · Jan 2025

Apheris provides governed, private, and secure access to data for machine learning and analytics, targeting the life sciences sector. Its core product, the Apheris Compute Gateway, ensures only approved computations can be launched on sensitive data and enables federation across organizational boundaries. The gateway allows ML-powered insights without centralizing data while maintaining compliance with data privacy, security, and governance obligations. The company was co-founded by Robin Röhm (CEO) and Michael Höh (CTO) and is based in Berlin, Germany. Apheris raised $20.8M in a Series A round and intends to use the proceeds to expand operations and development efforts. No operating metrics were disclosed in the article. Apheris provides a platform for creating collaborative data ecosystems that lets multiple organizations extract value from each other’s decentralized data sets. The platform is designed to help partners overcome regulatory, technical and commercial challenges when sharing or analyzing data. The company says it will use the new funding to further develop its technology and expand its roster of customers and partners. Customers and partners named in the article include BASF, Boston Consulting Group, BMW Group and JLABS. Financially, Apheris completed a €8.7M Seed extension in August 2022. The company was founded in 2019 by Robin Röhm and Michael Höh and is based in Berlin. Apheris provides a privacy-preserving data platform that applies decentralised computing, federated learning and cryptographic protocols to protect data in low- or zero-trust environments. Its platform is used by international customers for drug discovery, new product R&D and supply chain optimisation across pharmaceutical, chemical, telecommunications and manufacturing sectors. The company plans to use the new funds to hire engineers, R&D data scientists and customer success staff and to address new industry use cases. Apheris was founded in January 2019 and is based in Berlin. The team comprises ten PhDs, data scientists and engineers with domain expertise. The company is already profitable and working with leading enterprise customers.

Led · Seed · Nov 2024

Heim Health operates an API-led software platform that sources highly skilled nurses and other practitioners to deliver care in patients' homes, supporting appointments such as blood tests, post-operative assessments and injections. Its proprietary assignment algorithms and technology aim to unlock latent workforce capacity, make home-based care cost-effective and reduce pressure on hospital staff. Patients access a simple interface to book, change or cancel at-home appointments, improving access for older people and those with mobility or additional needs. Heim partners with both private healthcare organisations and the NHS to manage end-to-end delivery and scale community-based care. The company cites that 13% of NHS beds are occupied by people who could receive care in the community, underpinning its mission to shift more care into the home. Heim was formerly known as Ally Health and was founded by the team behind the Testing For All not-for-profit Covid testing service.